Trump and HHS Secretary Link Acetaminophen to Autism
President Donald Trump, alongside Department of Health and Human Services Secretary Robert F. Kennedy Jr., ignited a debate among medical professionals and certain liberal groups by declaring acetaminophen a potential contributor to the increasing autism rates in the U.S.
Commonly known as Tylenol in the U.S., acetaminophen is referred to as paracetamol in other countries and is frequently used as an over-the-counter pain relief option during pregnancy. This year, acetaminophen sales were valued at about $10.9 billion.
Kennedy mentioned that the U.S. Food and Drug Administration (FDA) plans to alert healthcare providers about possible links between acetaminophen use during pregnancy and serious neurological conditions in children, like autism and ADHD.
The Department of Health and Human Services is also set to initiate a nationwide campaign aimed at informing parents about the risks involved with taking Tylenol while pregnant. “The Trump administration believes that relying solely on medications isn’t always the best approach to health,” White House Press Secretary Caroline Leavitt mentioned. “We’re seeing increasing evidence that ties acetaminophen use in pregnancy to autism, so it’s important to share this new health guidance.”
In response, health officials from other countries quickly defended the drug, asserting its safety and efficacy. Allison Cave, Chief Safety Officer for the UK’s Pharmaceutical and Healthcare Products Regulatory Agency, stated, “There is no evidence that using paracetamol during pregnancy causes autism in children.”
Cave added that paracetamol should still be the go-to pain relief choice for pregnant women when used as directed. The UK’s MHRA also reinforced that patients should continue using painkillers as needed.
Steffen Thirstrup, Chief Medical Officer of the European Medicines Agency, echoed these sentiments, noting that acetaminophen serves as a critical option for managing pain and fever during pregnancy, with advice hinging on rigorous scientific assessments showing no link to autism.
World Health Organization representative Tarik Jasarevic indicated that while some studies have hinted at connections between prenatal drug exposure and autism, the evidence remains inconclusive. “If there were a strong connection between acetaminophen and autism, we would expect to see consistent findings across multiple studies,” he remarked.
James Cusack, CEO of a London-based autism research charity, stated that there’s no solid evidence to prove that paracetamol use in expecting mothers leads to autism, asserting that the correlation appears minimal.
As the discourse continues, some critics, particularly among liberal groups, have voiced their disapproval. In protest, some demonstrated by squeezing acetaminophen bottles. Various videos circulating online showcase both humorous takes on the issue and serious criticisms of the administration’s focus on autism’s underlying factors.
Dr. William Parker from UNC emphasized the need for sound scientific processes in this discussion, noting that there’s a significant body of research indicating acetaminophen could lead to autism spectrum disorders, particularly in susceptible children.
Additionally, Dr. Yuelong Ji, a researcher at Peking University, advocated for cautious use of acetaminophen during pregnancy based on findings that suggested fetal exposure increases the risk of childhood ADHD and autism.
The White House fact sheet referenced research by Parker and Ji, highlighting systematic reviews from the NIH that associate acetaminophen with both ADHD and autism risks, further suggesting pregnant women minimize their exposure to this common medication.
